Novo Nordisk A/S 2016 IR
The report outlines Novo Nordisk's financial, social, and environmental performance for the fiscal year 2016. Key highlights include the presentation of positive cardiovascular outcomes data for Victoza and semaglutide, alongside the regulatory filing of semaglutide in the US and EU. Despite facing a challenging pricing environment in the US, the company expanded its global patient reach to an estimated 28 million people with diabetes. On the environmental front, Novo Nordisk reduced its CO2 emissions from energy consumption by 14% and maintained a 78% share of renewable power for production.
Company: Novo Nordisk A/S
Sector: Manufacturing
Country: Denmark
Year: 2016
Type: IR
Pages: 121
Back to company
Novo Nordisk A/S
Annual Report
The report outlines Novo Nordisk's financial, social, and environmental performance for the fiscal year 2016. Key highlights include the presentation of positive cardiovascular outcomes data for Victoza and semaglutide, alongside the regulatory filing of semaglutide in the US and EU. Despite facing a challenging pricing environment in the US, the company expanded its global patient reach to an estimated 28 million people with diabetes. On the environmental front, Novo Nordisk reduced its CO2 emissions from energy consumption by 14% and maintained a 78% share of renewable power for production.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women in Management
Workplace Fatalities
Employees